Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Prostatic Neoplasms 64Lymphoma, Large B-Cell, Diffuse 47Lymphoma 33Burkitt Lymphoma 27Lymphoma, Follicular 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Lymphoma, Non-Hodgkin 14Neoplasms 13Lymphoma, B-Cell 11Lymphoma, T-Cell, Peripheral 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Hodgkin Disease 9Lymphoma, B-Cell, Marginal Zone 8Leukemia 8Recurrence 6Prostatic Neoplasms, Castration-Resistant 6Multiple Myeloma 6Leukemia, Lymphocytic, Chronic, B-Cell 6Neoplasm Metastasis 5Leukemia, Biphenotypic, Acute 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoproliferative Disorders 4Lymphoma, T-Cell 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Anaplastic 4Immunoblastic Lymphadenopathy 4Ovarian Neoplasms 3Myasthenia Gravis 3Metastatic Castration-resistant Prostate Cancer 3Melanoma 3

Interventions

Cyclophosphamide 9glofitamab 4Whole-Body Irradiation 4Rituximab 4fludarabine phosphate 3fludarabine 3Mycophenolic Acid 3Melphalan 3Doxorubicin 3polatuzumab vedotin 2pirtobrutinib 2pembrolizumab 2obinutuzumab 2Tacrolimus 2Sirolimus 2Prednisone 2Busulfan 2zanubrutinib 1venetoclax 1relmacabtagene autoleucel 1pegfilgrastim 1axicabtagene ciloleucel 1Vincristine 1Triamcinolone 1Specimen Handling 1Receptors, Chimeric Antigen 1Prednisolone 1Peripheral Blood Stem Cell Transplantation 1Oxaliplatin 1Methotrexate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Dendritic Cell Sarcoma, Interdigitating × Prednisone × 1 year × Clear all
NCT07231250 2025-11-19

Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

Sun Yat-sen University

Phase 2 Not yet recruiting
40 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

NCT07034508 2025-06-24

A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Not yet recruiting
134 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡